Search the Newsreel

Is Alto Neuroscience (ANRO) Fully Valued As ALTO 207 Expands With New Funding?

11,096 Shares in Marathon Petroleum Corporation $MPC Bought by Centric Wealth Management

Centric Wealth Management recently purchased 11,096 shares of Marathon Petroleum Corporation (MPC), valued at approximately $2.8 million, marking a new position for the firm. This comes as Marathon Petroleum reported strong quarterly earnings, beating analyst estimates, and maintains a "Moderate Buy" consensus rating among …

HighTower Advisors LLC Sells 34,826 Shares of Occidental Petroleum Corporation $OXY

HighTower Advisors LLC reduced its stake in Occidental Petroleum Corporation by 5.1% in the second quarter, selling 34,826 shares. Despite this, other hedge funds increased their holdings, and institutional investors collectively own 88.70% of the company's stock. Occidental Petroleum reported strong Q2 earnings, increased …

Is Ionis Pharmaceuticals (IONS) Undervalued Following Its Pullback?

Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ionis Pharmaceuticals stock carries a strong three year return record alongside a high overall value score, yet current market multiples still point to the shares …

Mineralys Therapeutics, Inc. $MLYS Shares Bought by Bank of America Corp DE

Is It Smart To Buy Bank Leumi le-Israel B.M. (TLV:LUMI) Before It Goes Ex-Dividend?

Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts

Phathom Pharmaceuticals (PHAT) has experienced a modest fair value cut from US$23.70 to US$21.50 following analyst target revisions. This adjustment is due to updated Q2 results, revised 2026 revenue guidance, and new perspectives on their drug Voquezna's commercial path. While some firms remain bullish …

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Brokerages

Tarsus Pharmaceuticals (NASDAQ:TARS) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $90.50, significantly higher than its current share price of $69.20. The company recently reported quarterly revenue of $173.91 million, surpassing estimates, but its loss per …

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination

Citius Pharmaceuticals reported promising early results for its approved drug LYMPHIR in new indications, including an 86% objective response rate in a Phase 1 CAR-T combination trial for diffuse large B-cell lymphoma and a 24% ORR in gynecologic malignancies. The company also announced strong …

Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative?

Mirum Pharmaceuticals reported a significant net loss for Q2 and H1 2026, with basic loss per share rising, which highlights increased costs relative to revenue. This widening loss intensifies focus on cash burn and funding risks, despite upcoming clinical and regulatory catalysts such as …

Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Sell

Wall Street Zen has downgraded Mirum Pharmaceuticals (NASDAQ:MIRM) from "hold" to "sell," despite the company reporting better-than-expected quarterly revenue of $176.24 million, a 37.9% increase year-over-year. The downgrade comes as the company missed earnings per share estimates, reporting a loss of $1.06 against a …

Wall Street Zen Upgrades Avalo Therapeutics (NASDAQ:AVTX) to Hold

Wall Street Zen has upgraded Avalo Therapeutics (NASDAQ:AVTX) from a "sell" to a "hold" rating, though the consensus among other analysts remains a "Moderate Buy" with an average price target of $45.10. The company reported a quarterly loss of $0.83 per share, missing estimates. …

Responsive Playbooks and the ETON Inflection

This article provides an AI-driven analysis for Eton Pharmaceuticals Inc. (NASDAQ: ETON), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report suggests …

Atara Biotherapeutics (NASDAQ:ATRA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen has upgraded Atara Biotherapeutics (NASDAQ:ATRA) from "Sell" to "Hold," reflecting an average "Hold" consensus among analysts with an average price target of $9.50. Despite the upgrade, ATRA shares opened down 4.9% at $8.09, with the company reporting a quarterly loss of …

Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope

Rigel Pharmaceuticals (RIGL) has seen its fair value estimate increase from US$51.6 to US$61.2 per share, primarily due to the launch of Veppanu in the U.S. and the international potential of Rezlidhia through a partnership with Kissei. Analysts, such as H.C. Wainwright, view Veppanu …

Why Eton Pharmaceuticals (ETON) Is Up 32.0% After Q2 Earnings Surge And Raised 2026 Outlook

Eton Pharmaceuticals (ETON) saw its stock rise 32.0% after reporting a significant Q2 2026 earnings turnaround, with revenue surging to US$37.59 million and net income reaching US$11.58 million. The company also raised its full-year 2026 revenue guidance to at least US$145 million and expanded …

Should I buy Scribe Therapeutics Inc. (SCTX)

Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – DUS:1RV

This article provides financial data for Rhythm Pharmaceuticals, Inc. (DUS:1RV) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to revenue forward. It notes that the market is closed with no trades recorded at the time of publication. The content is presented …

Price-Driven Insight from (ZVRA) for Rule-Based Strategy

This article provides a price-driven analysis for Zevra Therapeutics Inc. (NASDAQ: ZVRA), highlighting weak near-term sentiment but strong mid and long-term outlooks. It details institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, and an exceptional risk-reward short …

Arcutis (ARQT) Q2 2026 Earnings Call Transcript

Eureka Forbes Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nektar Therapeutics (NKTR) Stock Slides As Cash Burn Clouds Pipeline Progress

Nektar Therapeutics' stock fell 4% following its Q2 2026 earnings report, despite progress in its autoimmune pipeline, notably rezpegaldesleukin. The market reacted negatively to the company's substantial cash burn, with a quarterly net loss exceeding US$40 million and trailing 12-month losses widening. While the …

Technical Reactions to NGNE Trends in Macro Strategies

This article analyzes Neoleukin Therapeutics Inc. (NASDAQ: NGNE) using AI models to develop distinct trading strategies. It highlights a strong near-term sentiment potentially leading to a long-term positive bias, with an exceptional risk-reward short setup. The analysis provides specific entry, target, and stop-loss levels …

Grupo Mateus SA (BSP:GMAT3) (Q2 2026) Earnings Call Highlights: Resilient Growth Amid Macro ...

This article first appeared on GuruFocus. Release Date: August 14, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Grupo Mateus SA (BSP:GMAT3) reported strong revenue growth of 8% in the second quarter, driven …

How Rapport Therapeutics Inc. (RAPP) Affects Rotational Strategy Timing

This article analyzes Rapport Therapeutics Inc. (RAPP) using AI models to determine its effect on rotational strategy timing. Key findings suggest a strong sentiment supporting an overweight bias, with resistance being tested. The analysis provides specific institutional trading strategies, including position trading, momentum breakout, …

What Does Lantheus Holdings (LNTH) FDA Approval Mean For Its Alzheimer’s Push?

Lantheus Holdings received FDA approval for TAUKLARIFY, a tau PET imaging agent for Alzheimer's disease diagnostics, expanding its molecular imaging portfolio beyond prostate cancer. This approval strengthens Lantheus's position in the Alzheimer's imaging market and supports its strategy of diversifying revenue and meeting the …

Marathon Petroleum (MPC) legt nach massivem Gewinnsprung im zweiten Quartal und fast vollständigem Aktienrückkauf um 19,2 % zu – Hat sich das bullische Szenario geändert?

Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates

Vivos Therapeutics, Inc. (VVOS) reported a Q2 loss of $0.31 per share, which was better than the Zacks Consensus Estimate of a $0.42 loss. However, the company missed revenue estimates, posting $5.15 million against an expected $5.43 million. Despite beating EPS estimates two out …

How TG Therapeutics’ Q2 2026 Revenue Surge And Higher Guidance At TG Therapeutics (TGTX) Has Changed Its Investment Story

Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker

An insider at Zevra Therapeutics (ZVRA) has filed a Form 144 notice to resell up to 42,666 common shares. These shares are linked to restricted stock units granted in June 2025 and are planned for potential sale on NASDAQ. The filing also references previous …

Shanghai Fudan Zhangjiang Bio Pharmaceutical Ltd (SEHK:1349) Stock Profit Rebound Raises Durability Questions

Sasseur REIT (SGX:CRPU) Stock Revenue Holds Firm As Margins Tighten

Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat

ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal

What date does Scribe Therapeutics Inc.'s (SCTX) report Earnings - Earnings Calendar & Announcement